In the subgroup analysis, we found that the high expression of TUG1 was related to poor OS of patients with gastrointestinal cancers (ESCC, GC, CRC, PC, HCC, and CCA), gynecological tumors (BC, OC, CC, and EC), hematological tumors (AML and NHL), urinary tumors (RCC, BLC, UC, and PCa), and OSA. Here, TUG1 is linked to colorectal carcinoma.